. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: J Allergy Clin Immunol. 2011 Nov 21;129(1):112–118. doi: 10.1016/j.jaci.2011.10.030

TABLE III.

Effect of adherence to study treatment on differences in outcomes between the budesonide and placebo treatment groups within the ancillary study

	Treatment group–adherence_4yrs interaction, P value^*
Clinical outcomes
Urgent care visits caused by asthma (yes vs no); odds ratio	.58
No. of courses of prednisone (no./100 person years)	.56
Percentage of days on beclomethasone or other asthma medications	.71
Change in daily diary card measures
Symptom score	.84
Asthma episode-free days (no./mo)	.61
Use of albuterol for symptoms (puffs/wk)	.30
Nighttime awakenings (no./mo)	.58
Pulmonary function
Changes in spirometric values before bronchodilator
FEV₁ (L)	.24
FEV₁ (% predicted)	.02
FVC (L)	.32
FEV₁/FVC ratio (%)	.30
Changes in spirometric values after bronchodilator
FEV₁ (L)	.38
FEV₁ (% predicted)	.03
FVC (L)	.61
FEV₁/FVC ratio (%)	.26
Airway responsiveness to methacholine, ratio of follow-up to baseline values	.25
Height and bone density
Change in height (cm)	.41
Change in height percentile	.31
Projected final height (cm)	.20
Change in bone mineral density (g/cm²)	.46

Values represent P values for interaction between treatment group and adherence_4yrs values in multivariable regression models (see the Methods section).